Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) CEO Interview with James F. Oliviero discussing clinical progress in company’s pipeline of cancer drugs, addressing multi-billion dollar markets. The company’s lead drug is in late stage clinical trials, with potential commercialization within next 3 years.
Investor Presentation
VANCOUVER, Washington, Feb 01, 2019 — Successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from CD02-Extension study from 350 mg to […]
INCHEON, South Korea, May 30, 2019 – CytoDyn Inc., (OTC: CYDY) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications and Samsung BioLogics met at […]
VANCOUVER, Washington and NEW YORK, Dec 17, 2019 – In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
